Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03258554 | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | completed | Phase 2 / Phase 3 | 196 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07435324 | A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma | completed | Phase 3 | 161 | R-PharmINDUSTRY | 2 | Jul 14, 2026 |
| clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT01864850 | Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC(ELAN-RT) | completed | Phase 3 | 202 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 2 | Sep 22, 2023 | clinicaltrials |
| NCT05802290 | NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN(NIVACTOR) | completed | Phase 3 | 124 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT00274937 | Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer | completed | Phase 3 | 111 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT02105636 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | completed | Phase 3 | 361 | Bristol-Myers SquibbINDUSTRY | 15 | Oct 5, 2022 | clinicaltrials |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity(IT-MATTERS) | completed | Phase 3 | 928 | CEL-SCI CorporationINDUSTRY | 23 | Aug 19, 2022 | clinicaltrials |
| NCT01950689 | NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)(NIMRAD) | completed | Phase 3 | 338 | The Christie NHS Foundation TrustOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT02551159 | Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer(KESTREL) | completed | Phase 3 | 823 | AstraZenecaINDUSTRY | 23 | Oct 13, 2021 | clinicaltrials |
| NCT03349710 | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | completed | Phase 3 | 74 | Bristol-Myers SquibbINDUSTRY | 10 | Aug 9, 2021 | clinicaltrials |
| NCT01427478 | Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck(BIBW2992ORL) | completed | Phase 3 | 134 | Centre Leon BerardOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT00609284 | Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux(2007-01) | completed | Phase 3 | 406 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Apr 15, 2020 | clinicaltrials |
| NCT04137627 | Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma | completed | Phase 3 | 50 | Indonesia UniversityOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT02715596 | Changes in Body Composition After EPA Supplementation in Head and Neck Patients(hepaneck) | completed | Phase 3 | 54 | Institut Català d'OncologiaOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT00442455 | Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck | completed | Phase 3 | 53 | Grupo de Investigación Clínica en Oncología RadioterapiaOTHER | 1 | Jun 6, 2019 | clinicaltrials |
| NCT02347332 | Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer | completed | Phase 3 | 459 | Pierre Fabre MedicamentINDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01233843 | Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.(2007/02) | completed | Phase 3 | 370 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01542931 | TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 256 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT00174837 | TRACE: Tirapazamine-Radiation And Cisplatin Evaluation(TRACE) | completed | Phase 3 | 317 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT01012258 | Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects(CHANCE) | completed | Phase 3 | 70 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jul 9, 2015 | clinicaltrials |
| NCT01086826 | Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck(H&N07) | completed | Phase 3 | 320 | Associazione Volontari Pazienti OncologiciOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT01177956 | A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck(CHANGE) | completed | Phase 3 | 73 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Sep 3, 2014 | clinicaltrials |
| NCT01439724 | Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients | completed | Phase 3 | 94 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Apr 11, 2014 | clinicaltrials |
| NCT00206219 | Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) | completed | Phase 3 | 477 | AstraZenecaINDUSTRY | 25 | Jan 27, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Aug 27, 2026source: clinicaltrials